The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ICML 2021 | PET scans in NHL
Sally F. Barrington, MBBS, MSc, FRCP, FRCR, MD, King’s College London, London, UK, discusses the role of positron emission tomography (PET) in treating the most common subtypes of non-Hodgkin lymphoma (NHL), such as diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and T-cell lymphoma. PET scans can assess remission status after treatment by comparing post-treatment scans to baseline scans taken before treatment. Patients with DLBCL who were staged with PET scans additionally had superior overall survival (OS), emphasizing the prognostic role of PET scans. This interview took place during the 2021 International Conference on Malignant Lymphoma (16-ICML).
